Show simple item record

dc.contributor.authorMcDowell, Arlene
dc.contributor.authorMedlicott, Natalie
dc.contributor.authorFothergill, Jessica
dc.contributor.authorKhan, Azeem
dc.date.available2021-09-14T20:34:38Z
dc.date.copyright2014
dc.identifier.citationMcDowell A, Fothergill JA, Khan A and Medlicott NJ and (2014). A cyclodextrin formulation to improve use of the anaesthetic tribromoethanol (Avertin®). Theme Issue of the Journal of Pharmacy and BioAllied Sciences 6: 16-21en_NZ
dc.identifier.urihttp://hdl.handle.net/10523/12266
dc.description.abstractObjective: Efficacy and safety concerns have been raised in the literature with the use of tribromoethanol (Avertin) for anaesthesia in rats and mice when administered by intraperitoneal injection. Despite the controversy, it remains in common usage as an anaesthetic agent in laboratory rodents for short-term surgical procedures. Cyclodextrins have been shown to improve drug solubility and were investigated here as an improved anaesthetic formulation for mice. Materials and Methods: The phase solubility of TBE with HP-β-CD was estimated. The efficacy of two anaesthetic regimens were compared in this study; the conventional tribromoethanol (TBE) formulation solubilized in tertiary amyl alcohol and a HP-β-CD cyclodextrin formulation containing TBE. Mice (n=6) were administered the formulations by IP injection and the pharmacodynamic parameters of time to induction of anaesthesia, duration of anaesthesia and recovery time were measured using a combined reflex score. Results and Discussion: Phase solubility studies showed a linear increase in the solubility of TBE with increasing HP-β-CD concentration and suggested > 1:1 binding of the drug in the cyclodextrin complex. At a dose of 260 mg/kg the standard TBE formulation appeared to produce deeper anaesthesia than the cyclodextrin formulation, with a minimum average CRS of 1.8 compared to 5.2. No post-mortem pathology was observed in mice that received either the conventional or cyclodextrin formulation. Conclusion: The cyclodextrin TBE formulation did not conclusively provide an improved anaesthetic response at a dose of 260 mg/kg compared to the conventional formulation. The improved solubility of TBE with HP-β-CD and the reduced variability in anaesthetic response warrants the further investigation of this formulation. This study has also identified the value of using the anticholinergic atropine in association with TBE for anaesthesia.en_NZ
dc.format.mimetypeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
dc.language.isoenen_NZ
dc.publisherMedknow Publicationsen_NZ
dc.relation.ispartofJournal of Pharmacy and BioAllied Sciencesen_NZ
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCyclodextrinen_NZ
dc.subjectsolubilityen_NZ
dc.subjecttribromoethanolen_NZ
dc.subjectanaestheticen_NZ
dc.subjectmiceen_NZ
dc.titleA cyclodextrin formulation to improve use of the anaesthetic tribromoethanol (Avertin)en_NZ
dc.typeJournal Articleen_NZ
dc.date.updated2021-09-14T05:29:29Z
otago.schoolSchool of Pharmacyen_NZ
otago.relation.volume6en_NZ
otago.bitstream.endpage21en_NZ
otago.bitstream.startpage16en_NZ
otago.openaccessOpenen_NZ
dc.rights.statementThis version in OUR Archive is the author’s manuscript accepted for publication after peer-review. The published version is: McDowell A, Fothergill JA, Khan A and Medlicott NJ and (2014). A cyclodextrin formulation to improve use of the anaesthetic tribromoethanol (Avertin®). Theme Issue of the Journal of Pharmacy and BioAllied Sciences 6: 16-21en_NZ
dc.description.refereedPeer Revieweden_NZ
 Find in your library

Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International